Can Oral Gildeuretinol Slow Advanced Macular Degeneration? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.

  • By

  • Andrea Surnit

  • July 20, 2026

  • 3 min

Share

  • 1

    Oral gildeuretinol acetate did not significantly slow geographic atrophy progression compared to placebo in age-related macular degeneration patients.

  • 2

    The phase 2/3 SAGA trial involved 198 patients aged 60 and older, assigned to receive either gildeuretinol or placebo for 24 months.

  • 3

    Geographic atrophy lesion growth was reduced by 13% with gildeuretinol, but this difference was not statistically significant.

  • 4

    Secondary outcomes showed exploratory benefits for gildeuretinol, including less decline in low-luminance visual acuity and improved quality of life.

  • 5

    The study's primary endpoint was not met, and researchers emphasized that secondary findings are exploratory and require further investigation.

Original Source(s)

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

  • by Andrea Surnit

  • July 20, 2026

Related Content

Blindness Linked to Higher Loneliness Scores

Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Medical Oddities: The Economics of Shut-Eye

Sleep became a commodity, tea became a therapy, and cats got a reprieve this week.